AtriCure (NASDAQ:ATRC) Director Sells $180,000.00 in Stock

AtriCure, Inc. (NASDAQ:ATRC) Director Sven Wehrwein sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $36.00, for a total value of $180,000.00. Following the completion of the transaction, the director directly owned 34,374 shares in the company, valued at approximately $1,237,464. This trade represents a 12.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

AtriCure Price Performance

Shares of ATRC opened at $37.66 on Friday. AtriCure, Inc. has a 52-week low of $24.48 and a 52-week high of $43.11. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.83 and a current ratio of 3.94. The business’s 50 day moving average price is $33.05 and its two-hundred day moving average price is $33.88. The firm has a market cap of $1.87 billion, a PE ratio of -48.91 and a beta of 1.61.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings results on Tuesday, July 29th. The medical device company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.13. AtriCure had a negative return on equity of 4.20% and a negative net margin of 7.27%.The firm had revenue of $136.14 million for the quarter, compared to analyst estimates of $130.17 million. During the same period in the previous year, the firm earned ($0.17) earnings per share. The company’s revenue was up 17.1% compared to the same quarter last year. AtriCure has set its FY 2025 guidance at -0.390–0.340 EPS. On average, equities analysts anticipate that AtriCure, Inc. will post -0.6 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Wall Street Zen raised AtriCure from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. BTIG Research set a $54.00 price target on AtriCure in a research note on Wednesday, July 30th. JMP Securities reaffirmed a “market outperform” rating and set a $60.00 target price on shares of AtriCure in a research report on Wednesday, April 30th. Needham & Company LLC upped their target price on AtriCure from $44.00 to $45.00 and gave the stock a “buy” rating in a research report on Wednesday, July 30th. Finally, UBS Group lowered their target price on AtriCure from $60.00 to $58.00 and set a “buy” rating on the stock in a research report on Wednesday, April 30th. Nine equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, AtriCure has an average rating of “Buy” and a consensus target price of $50.89.

Institutional Investors Weigh In On AtriCure

Institutional investors and hedge funds have recently bought and sold shares of the stock. Ameriprise Financial Inc. purchased a new stake in AtriCure in the 4th quarter valued at $295,000. Envestnet Asset Management Inc. raised its position in AtriCure by 22.9% in the 1st quarter. Envestnet Asset Management Inc. now owns 56,656 shares of the medical device company’s stock valued at $1,828,000 after buying an additional 10,570 shares during the last quarter. Assenagon Asset Management S.A. raised its position in AtriCure by 5.0% in the 1st quarter. Assenagon Asset Management S.A. now owns 146,096 shares of the medical device company’s stock valued at $4,713,000 after buying an additional 6,995 shares during the last quarter. GAMMA Investing LLC raised its position in AtriCure by 9,664.9% in the 1st quarter. GAMMA Investing LLC now owns 3,613 shares of the medical device company’s stock valued at $112,000 after buying an additional 3,576 shares during the last quarter. Finally, Victory Capital Management Inc. purchased a new stake in AtriCure in the 1st quarter valued at $1,847,000. 99.11% of the stock is owned by hedge funds and other institutional investors.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.